

David Huberman



Partner

Tel Aviv

972-3-7955580

davidh@zag-sw.co.il

Practices

- Capital Markets
- Corporate
- Life Sciences
- Mergers & Acquisitions

About

David Huberman is a partner in the International Department of our Tel Aviv office, and a member of our Capital Markets and Finance practice groups.

David focuses on U.S. securities law and capital market transactions. He advises many technology and pharmaceutical companies and provides comprehensive legal counsel on all aspects of U.S. corporate and securities law, including public offerings. David provides ongoing advice to many Israeli companies listed on Nasdaq.

Education

- J.D., Chicago-Kent College of Law

Bar Admissions

- Illinois, 2011
- Israel, 2013

Representative Client Work

- Represented **Nano Dimension Ltd.** (Nasdaq, TASE: NNDM) in several offerings of American Depositary Shares – **\$13M** in February 2018, **\$12M** in February 2019, and a debt offering of **\$7M** in September 2019.
- Represented **Safe-T Group Ltd.** in its **\$10MS** IPO and dual listing on the Nasdaq Capital Market, its acquisition of Net Nut Ltd. in June 2019, and debt offering of **\$5M** in June 2019.
- Represented **Foresight Autonomous Holdings Ltd.** in a private placement of **NIS 20M** in June 2018, and a **\$6.2M** offering of American Depositary Shares in March 2019.
- Represented **Therapix Biosciences Ltd.** in its U.S. IPO, including its dual listing on the Nasdaq Capital Market, and a follow on offering in April 2019.
- Represented **Radcom Ltd.** in two public offering of ordinary shares – October 2017-**\$28M** and May 2016 **\$20M**.
- Represented investment bank **Rodman & Renshaw** as an underwriter in a public offering.

- Represented **Bioblast Pharma Ltd.** in its registered direct offering of ordinary shares.
- Represented **On Track Innovations Ltd.** in its public offering of ordinary shares.